Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH2043 in Advanced Malignant Tumors
NCT05728541Phase 1Not yet recruiting
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- Mar 2023
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SYH2043 in advanced malignant solid tumor, breast cancer, ovarian cancer and 1 more (2 arms), sponsored by CSPC Ouyi Pharmaceutical. Primary endpoints: Adverse Events, Serious Adverse Events and 3 more. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
SYH2043
03
Conditions
advanced malignant solid tumorbreast cancerovarian cancerliver cancer
Beyond the preview
Go deeper on NCT05728541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05728541.